Medicine Introduction Center

Posts Tagged ‘market’

The industry analysis specialist’s new report, “Alzheimer’s Disease – Drug Pipeline Analysis and Market Forecasts to 2015″ is an essential source of information and analysis on the global Alzheimer’s disease market. The report identifies the key trends shaping and driving the dynamism in the global Alzheimer’s disease market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global Alzheimer’s disease sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by  team of industry experts. ScopeThe scope of the report includes:- Annualized global Alzheimer’s disease market revenues data from 2000 to 2008, forecast forward for 7 years to 2015. – Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan. – Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. Key classes of mechanism of action include immunotherapy, NMDA agonists, acetylcholine inhibitors, gamma secretase modulators, serotonin receptor antagonists, muscarinic receptor agonists, alpha secretase enhancers, beta secretase inhibitors, tau inhibitors and non-steroidal anti-inflammatory classes of drugs. – Analysis of the current and future market competition in the global Alzheimer’s disease market. Each trend is independently researched to provide qualitative analysis of what the implications on sectors are, and how are companies responding to these trends. – Insightful review of the future market players, key industry drivers, restraints and challenges which are likely to impact the Alzheimer’s disease therapeutics market in the long run. Key future market players covered are Wyeth, Elan, Astrazeneca, Medivation and Baxter Healthcare. – Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with Alzheimer’s disease. Reasons to buyThe report will enhance your choice making capability in a more rapid and time sensitive manner. It will allow you to:- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline. – Develop business strategies by understanding the trends shaping and driving the global Alzheimer’s disease market. – Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global Alzheimer’s disease market in future. – L2Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. – Identify emerging players with potentially strong product portfolio and make effective counter-strategies to gain competitive advantage. – Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. – What’s the next huge thing in the global Alzheimer’s disease market landscape? – Identify, know and capitalize. ” $2,000 $4,000 $6,000 GDHCPRT005 Pharmaceuticals and Healthcare Market forecast, revenues, unmet need, drivers, barriers, pharma, clinical trials, marketed products, pipeline, promising drugs, future players, key companies, strategic competitor assessment, market characterization, implications for future market, mechanism of action, immunotherapy, NMDA agonists, acetylcholine inhibitors, gamma secretase modulators, serotonin receptor antagonists, muscarinic receptor agonists, alpha secretase enhancers, beta secretase inhibitors, tau inhibitors and non-steroidal anti-inflammatory classes of drugs  

For more information,please visit:

http://www. aarkstore. com/reports/Alzheimer’s-Disease-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2015-40570. html

 

The industry analysis specialist’s new report, “Psoriasis – Drug Pipeline Analysis and Market Forecasts to 2015″ is an essential source of information and analysis on the global psoriasis market. The report identifies the key trends shaping and driving the dynamism in the global psoriasis market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global psoriasis sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by team of industry experts. Estimated the psoriasis market to be worth $2. 4 billion in 2008 with projected CAGR of 7. 3% and projected market value to exceed $4. 1 billion in 2015. The psoriasis disease market is forecast to show high growth. This growth will be driven or supported by the increased prescription rate and uptake of biologics, more emerging therapies and diverse treatment options that will be available for patients in the near future. Barriers for the psoriasis market exist in terms of low diagnosis rate. The psoriasis market has relatively high unmet need largely driven by the poor safety profile of existing products. Found that there are over 125 molecules in various stages of the pipeline. Voclosporin, ABT-874, CF-10 are some of the late stage pipeline molecules. Orencia, Cimzia, Apremilast and INCB18424 are some of the promising therapies in the Phase II stage of the pipeline. These pipeline molecules differ in their target of action from the existing therapies. Patient perception of disease severity drives treatment-seeking behavior in the psoriasis market. New therapeutic options targeting specific mechanisms are set to reshape the psoriasis therapy. But, the current biologics have not undermined first-line topical therapy and hence there exists intensified competition between the current therapeutics and the emerging therapies. The pipeline has seen an increase in the development of emerging therapies like biologics as they have the ability to change the natural course of the disease. Emerging therapies have gained a positive perception among physicians in the maintenance of remission. There is likely to be a tremendous increase in the prescription of biologics due to increased awareness and also promising safety and efficacy results of promising therapies. The emerging therapies are likely to crowd the market and there is the possibility of price war. Found that the current competition in the psoriasis market is becoming intense due to the increased entry of biologics. It projects that Immunex Corporation, Abbott laboratories. Biogen Idec and Centocor will remain the leading competitiors of the global psoriasis biologics market. Compared to other autoimmune disease markets, this market has witnessed a greater entry of biologics. Though only a small segment of people tend to use biologics, their launch has increased competition in the psoriasis disease market. Amgen and Wyeth’s Enbrel is the market leader in the psoriasis disease market. It is followed by Abbott’s Humira, Leo Pharma and Warner Chiclott’s Dovonex, Centocor’s Remicade, Genentech’s Raptiva, Novartis’s Neoral (generic), followed by Allergan’s Tazorac, Biogen Idec’s Fumaderm and Biogen Idec and Astellas Pharma’s Amevive. Scope of the ReportScope of the report includes:

Annualized global psoriasis market revenues data from 2000 to 2008, forecast forward for 7 years to 2015.

Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.

Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. Key classes of mechanism of action include TNF-alpha inhibitors, interleukin inhibitors, vitamin D3 analogues, topical corticosteroids, enzyme inhibitors, immunomodulatory drugs, anti-inflammatory drugs, T cell modulators and ion channel modulators.

Analysis of the current and future market competition in the global psoriasis market. Each trend is independently researched to provide qualitative analysis of what the implications on sectors are, and how are companies responding to these trends.

Insightful review of the future market players, key industry drivers, restraints and challenges which are likely to impact the psoriasis therapeutics market in the long run. Key future market players covered are Isotechnika, Can-Fite Biopharma, UCB, Celgene Corporation, Incyte, Glaxosmithkline, Bristol-Myers Squibb, Leo Pharma, Novartis and Abbott Laboratories.

Key topics covered include promising drugs in the pipeline, strategic competitor assessment, market psoriasis.

Reasons to BuyThe report will enhance your choice making capability in a more rapid and time sensitive manner. It will allow you to:

Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global psoriasis market.

Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global psoriasis market in future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolio and make effective counter-strategies to gain competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

What’s the next huge thing in the global psoriasis market landscape? – Identify, know and capitalize.

For more information,please visit:

http://www. aarkstore. com/reports/Psoriasis-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2015-40536. html

The industry analysis specialist’s new report, “Neuropathic Pain – Drug Pipeline Analysis and Market Forecasts to 2015″ is an essential source of information and analysis on the global neuropathic pain market. The report identifies the key trends shaping and driving the global neuropathic pain market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global neuropathic pain sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by team of industry experts. Estimated the global neuropathic pain market to be valued at $4. 8 billion in 2008. It is expected to grow at a Compound Annual Growth Rate (CAGR) of approximately 4. 3% from $4. 8 billion in 2008 to $6. 5 billion in 2015. This growth will be supported by the increase in the aging population, increased treatment seeking behavior, increased uptake of the current products. Diagnosis rate remains as one of the barriers for the growth of the market. The available treatment options are moderately successful in meeting the market demand. There is still a need for better therapy and there exists the unmet need. There exists a market potential for any new entrant that will cater these unmet needs. There is enormous opportunity for any drug that would offer better or retain the efficacy provided by the current players with increased safety than the current products. Analyzed that there are over 111 molecules in various stages of the pipeline. Vimpat, Qutenza, Fentora are some of the pipeline candidates in the regulatory filing stage for approval. The late stage pipeline includes some of the promising molecules like Ralfinamide, NP-1, Sativex. These drugs may retain the similar efficacy and offer better safety and may benefit the patient population who cannot endure the available drugs. The newer therapies may intensify the existing competition and there seems to be a possibility of price war. Scope of the ReportThe scope of the report includes:

Annualized global neuropathic pain market revenues data from 2006 to 2008, forecast forward for 7 years to 2015.

Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.

Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. Key classes of mechanism of action includes opioid receptor agonists, cannabinoid receptor modulators, NMDA antagonists, protein kinase inhibitors, ion channel targetters, serotonin norepinephrine reuptake inhibitors, adenosine agonists, cytokine modulators, AMPA antagonists, nicotinic receptor agonists, TRPV1 receptor agonists, selective subtype sodium channel antagonists, iNOS/nNOS dual inhibitors.

Analysis of the current and future market competition in the global neuropathic pain market. Key future market players covered are NeurogesX, Cephalon Inc. , UCB S. A. , Newron Pharmaceuticals, EpiCept Corporation, GW Pharmaceuticals, Johnson & Johnson, Avanir pharmaceuticals, GlaxoSmithKline plc. , AstraZeneca.

Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with neuropathic pain.

Reasons to BuyThe report will enhance your choice making capability in a more rapid and time sensitive manner. It will allow you to:

Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global neuropathic pain market.

Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global neuropathic pain market in future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolio and make effective counter-strategies to gain competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

What’s the next huge thing in the global neuropathic pain market landscape? – Identify, know and capitalize.

For more information,please visit:

http://www. aarkstore. com/reports/Neuropathic-Pain-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2015-40530. html

The industry analysis specialist’s new report, “Non-Small Cell Lung Cancer (NSCLC) – Drug Pipeline Analysis and Market Forecasts to 2015″ is an essential source of information and analysis on the global NSCLC disease market. The report identifies the key trends shaping and driving the global NSCLC disease market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global NSCLC disease sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by  team of industry experts.  estimates the global NSCLC disease market to be $2. 8 billion in 2008. It is forecast to grow at a compound annual growth rate (CAGR) of 13. 5% for the next seven years to reach $6. 8 billion by 2015. This growth is primarily attributed to increased disease population and strong pipeline with more emerging therapies. The available treatment options are moderately successful in meeting the market demand. There exists a significant market potential to be tapped for any new entrant that will cater to the unmet needs. There is enormous opportunity for any drug that would offer better efficacy provided by the current players with increased safety than the current products. finds that that the emerging therapies in pipeline are expected to increase the competition. Emerging therapies have gained a positive perception among the physicians due to increased efficacy, safety and overall survival. The strong pipeline leads to the stiff competition in the NSCLC market and the existing market leaders need to be prepared to manage this expected dynamism in competition as there is a race to reach the blockbuster drug status. ScopeThe report analyzes market opportunities and challenges for the global NSCLC disease market. Its scope includes – Annualized global NSCLC disease market revenues data from 2000 to 2008, forecast forward for 7 years to 2015. – Geographic markets covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan. – Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. Key classes of mechanism of action includes tyrosine kinase inhibitors, microtubules, protein kinase inhibitors, cell division inhibitors, ERBB3 antagonist, DNA and RNA synthesis inhibitors, C-Met or ALK Inhibitors, glutathione S-transferase binders, growth and survival of MM cells inhibitors, HER2 dimerization inhibitors, antiangiogenesis inhibitors, cyclooxygenase-2 (COX-2) inhibitors, Pan Bcl-2 inhibitors and MUC1 tumor-associated antigens etc. – Analysis of the current and future market competition in the global NSCLC disease market. Key market players covered are F. Hoffmann-La Roche Ltd, Pfizer Inc. , Novartis AG, Sanofi-aventis, Boehringer Ingelheim GmbH, and Abraxis BioScience, Inc. – Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications. – Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with NSCLC disease. Reasons to buyThe report will enhance your choice making capability. It will allow you to:- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline. – Develop business strategies by understanding the trends shaping and driving the global NSCLC disease market. – Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global NSCLC disease market in future. – Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. – Identify emerging players with potentially strong product portfolio and make effective counter-strategies to gain competitive advantage. – Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. – What’s the next huge thing in the global NSCLC disease market landscape? – Identify, know and capitalize. ” $2,000 $4,000 $6,000 GDHCPRT020 Pharmaceuticals and Healthcare Market forecast, revenues, unmet need, drivers, barriers, pharma, clinical trials, marketed products, pipeline, promising drugs, future players, key companies, strategic competitor assessment, market characterization, implications for future market, mechanism of action, tyrosine kinase inhibitors, microtubules, protein kinase inhibitors, cell division inhibitors, ERBB3 antagonist, DNA and RNA synthesis inhibitors, C-Met or ALK Inhibitors, glutathione S-transferase binders, growth and survival of MM cells inhibitors, HER2 dimerization inhibitors, antiangiogenesis inhibitors, cyclooxygenase-2 (COX-2) inhibitors, Pan Bcl-2 inhibitors, MUC1 tumor-associated antigens  

For more information,please visit:

http://www. aarkstore. com/reports/Non-Small-Cell-Lung-Cancer-NSCLC-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2015-40590. html

The industry analysis specialist, has released a new report, “Ovarian Cancer – Drug Pipeline Analysis and Market Forecasts to 2016″. The report is an essential source of information and analysis on the global ovarian cancer market. The report identifies the key trends shaping and driving the global ovarian cancer market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to cause significant shifts in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global ovarian cancer sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by team of industry experts. Estimated the global ovarian cancer market to be valued at $697 million in 2009. It is forecast to grow by 13. 1% annually for the next seven years to reach $1,650 million by 2016. This growth is primarily attributed to high prescription rate of existing chemotherapy, strong pipeline and advancement of new targeted therapies. Analyzed that the global ovarian cancer market is moderately served with current product options and significant scope available to new entrants that would capture value from underserved segments. Designing curable products with high efficacy and safety profile is one of key challenges of this market and could provide significant market share for any company.   Analyzed that the global ovarian cancer market is increasingly becoming more competitive. Balancing the pipeline with the current marketed products and expectations of patients and physicians, the pipeline is considered to be strong. The unmet need in ovarian cancer market is high and if a company wants to capture this unmet need, it will need to overcome the prevailing product weaknesses and adverse effects. ScopeThe scope of the report includes:

Annualized global ovarian cancer market revenues data from 2001 to 2009, forecast forward 7 years to 2016.

Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.

Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. Key classes of mechanism of action includes topoisomerase inhibitor, drugs targeting DNA, vaccines, drugs targeting growth factor and growth factor receptors, folate receptor binder, kinase inhibitor, drugs targeting cytokines and combinations therapy.

Analysis of the current and future market competition in the global ovarian cancer market. Key market players covered are F. Hoffmann-La Roche Ltd/Genentech, Inc. , Menarini Group, Novartis AG, Cell Therapeutics Inc. , Telik, Inc. and BioNumerik Pharmaceuticals Inc.

Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with ovarian cancer.

Reasons to buyThe report will enhance your choice making capability in a more rapid and time sensitive manner. It will allow you to:

Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global ovarian cancer market.

Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global ovarian cancer market in future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolio and make effective counter-strategies to gain competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

What’s the next huge thing in the global ovarian cancer market landscape? – Identify, know and capitalize.

For more information,please visit:

http://www. aarkstore. com/reports/Ovarian-Cancer-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016-40533. html

The industry analysis specialist’s new report, “Periodontal disease – Drug Pipeline Analysis and Market Forecasts to 2016″ is an essential source of information and analysis on the global periodontal disease market. The report identifies the key trends shaping and driving the global periodontal disease market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global periodontal disease sector.   The global periodontal disease market was valued at $1,248m in 2009 and is characterized by efficacious dental procedures such as scaling, root planing and surgery. The periodontal therapeutics market comprises Local Applied Antibodies (LAAs) and systemic applied antibodies. The influx of new drugs and the increase in the uptake of LAAs will the drive the market in the forecast period. The various phases of the developmental pipeline contain 19 molecules. Of these, only five are in Phase III and the rest are in the early stages of development. The pipeline consists of no new antibiotics. The combinations of the tetracylines are expected to improve the efficacy of the treatment. But, the drug is similar in nature to doxycyclines. The entry of cost effective drugs in the forecast period is expected to aid the market growth.   This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.   Scope  The scope of the report includes:  - Annualized global periodontal disease market revenues data from 2001 to 2009, forecast for seven years to 2016.  - Geographies covered in this report are the United States (US), the United Kingdom (UK), Italy, Spain, Germany, France, and Japan.  - Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include tetracycline antibiotics, osteoblast stimulators and anti-inflammatories, H+/K+ ATPase inhibitors; cell wall synthesis inhibitors.  - Analysis of the current and future market competition in the global periodontal disease market. The key market players covered are Kaken Pharmaceutical, Fibrocell Science, Inc. , and Combinatorx, Inc.  - Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.  - Key topics covered include a strategic competitor assessment, market characterization, unmet needs and implications for the future periodontal disease market.   Reasons to buy  The report will enhance your choice making capability in a more rapid and time sensitive manner. It will allow you to: - Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.  - Develop business strategies by understanding the trends shaping and driving the global periodontal disease market.  - Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global periodontal disease market in future.  - Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.  - Identify emerging players with potentially strong product portfolio and make effective counter-strategies to gain competitive advantage.  - Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.  - What’s the next huge thing in the global periodontal disease market landscape? – Identify, know and capitalize.  

For more information, please contact :

http://www. aarkstore. com/reports/Periodontal-Disease-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016-40454. html

The industry analysis specialist’s new report, “Liver Cancer – Drug Pipeline Analysis and Market Forecasts to 2016″ is an essential source of information and analysis on the global liver cancer market. The report identifies the key trends shaping and driving the global liver cancer market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global liver cancer sector.   Analyzed that the liver cancer market has high unmet needs in terms of both efficacy and safety. More than 90% of patients diagnosed with liver cancer are between 45 years and 85 years of age. Nexavar is the only available Food and Drug Association (FDA) approved treatment for advanced liver cancer patients. But, the median survival time in patients treated with Nexavar is only three months more than for patients treated with placebo. Moreover, Nexavar has a low safety profile. About 39% and 6% of Nexavar-treated patients reported grade 3 and grade 4 adverse reactions respectively. Therefore, the unmet need in the liver cancer market was valued at 56%. This is expected to decrease significantly between 2009 and 2016 due to the expected launch of many first-in-class and me-too drugs. The majority of the first-in-class drugs are for the early stages of liver cancer and therefore they are expected to treat patients for whom no treatment options currently exist.   This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.   Scope  The scope of the report includes:  - Annualized global liver cancer market revenues data from 2001 to 2009, forecast forward for seven years to 2016.  - Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France and Japan.  - Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The first-in-class molecules are primarily Tumor Necrosis Factor Alpha (TNF-alpha) inhibitors, selective estrogen receptor modulators and light activated therapies.  - Analysis of the current and future market competition in the global liver cancer market. Key future market players covered are Bristol-Myers Squibb, Pfizer Inc. , F. Hoffmann-La Roche, Bayer Ag, Onyx Pharmaceuticals, Kowa Pharmaceuticals and Celsion Corporation.  - Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.  - Key topics covered include a strategic competitor assessment, market characterization, unmet needs and the implications for future market associated with the liver cancer market.   Reasons to buy  The report will enhance your choice making capability in a more rapid and time sensitive manner. It will allow you to: - Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.  - Develop business strategies by understanding the trends shaping and driving the global liver cancer market.  - Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global liver cancer market in future.  - Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.  - Identify emerging players with potentially strong product portfolio and make effective counter-strategies to gain competitive advantage.  - Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.  - What’s the next huge thing in the global liver cancer market landscape? – Identify, know and capitalize.

For more information, please contact :

http://www. aarkstore. com/reports/Liver-Cancer-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016-40455. html

HIV/AIDS – Drug Pipeline Analysis and Market Forecasts to 2016″ is an essential source of information and analysis on the global HIV/AIDS market. The report identifies the key trends shaping and driving the global HIV/AIDS market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global HIV/AIDS sector. GlobalData estimated the HIV/AIDS market was worth $12 billion in 2009. The global Human Immunodeficiency Virus (HIV) infection market will continue to grow between 2009 and 2016 at a slower rate due to a series of patent expiries during this period. The growth rate is likely to decline from 2012 onwards due to the impact of the patent expiry of key drugs. The market is characterized by a high unmet need of drugs which can cure the disease. Highly Active Antiretroviral Therapy (HAART) which requires patients to take different classes of drugs has but succeeded in achieving near zero levels of HIV in infected people. Increased uptake of HAART and increasing awareness (which leads to increased treatment seeking) will drive the market. The pipeline for HIV is strong and consists of more than 250 molecules currently in development for various disease segments. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts. Scope- Annualized global HIV/AIDS market revenues data from 2001 to 2009, forecast for seven years to 2016. – Geographies covered in this report are the United States (US), the United Kingdom (UK), Italy, Spain, Germany, France and Japan. – Pipeline analysis data providing a split across phases by mechanism of action, and the emerging trends. The key classes of mechanism of action include HIV vaccines, Nonnucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Multi-class Combination Products, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), CCR5 receptor antagonists, HIV integrase inhibitors, Nucleoside analogues, Viral entry inhibitors, Maturation inhibitors and Fusion Inhibitors. – Analysis of the current and future market competition in the global HIV/AIDS market. The key market players covered Boehring Ingelheim, Achillion Pharmaceuticals, GlaxoSmithKline, Incyte and Pharmasset, Shire Pharmaceuticals and Tibotec Virco – Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications. – The key topics covered include a strategic competitor assessment, market characterization, unmet needs and implications for the future HIV/AIDS market. Reasons to buyThe report will enhance your choice making capability in a more rapid and time sensitive manner. It will allow you to:- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline. – Develop business strategies by understanding the trends shaping and driving the global HIV/AIDS market. – Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global HIV/AIDS market in future. – Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. – Identify emerging players with potentially strong product portfolio and make effective counter-strategies to gain competitive advantage. – Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. – What’s the next huge thing in the global HIV/AIDS market landscape? – Identify, know and capitalize

For more information, please contact :

http://www. aarkstore. com/reports/HIV-AIDS-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016-40849. html

Fresenius Medical Care AG & Co. KGaA – SWOT Analysis company profile is the essential source for top-level company data and information. Fresenius Medical Care AG & Co. KGaA – SWOT Analysis examines the company’s key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy. Fresenius Medical Care (Fresenius or the company) is one of the world’s largest providers of products and services for individuals undergoing dialysis because of chronic kidney failure. It offers dialysis products such as hemodialysis machines, dialyzers and other disposable products. The company primarily operates in Germany and the US. It is headquartered in Terrible Homburg, Germany and employed 67,988 people as of December 2009. The company recorded revenues of $11,247. 5 million during the financial year (FY) finished December 2009, an increase of 6% over FY2008. The increase was due to growth in revenue in dialysis care segment. The operating profit of the company was $1,755. 6 million during FY2009, an increase of 5% over FY2008. The net profit of the company was $891. 1 million in FY2009, an increase of 9% over FY2008. Scope of the Report- Provides all the crucial information on Fresenius Medical Care AG & Co. KGaA required for business and competitor intelligence needs- Contains a study of the major internal and external factors affecting Fresenius Medical Care AG & Co. KGaA in the form of a SWOT analysis as well as a breakdown and examination of leading product revenue streams of Fresenius Medical Care AG & Co. KGaA-Data is supplemented with details on Fresenius Medical Care AG & Co. KGaA history, key executives, business description, locations and subsidiaries as well as a list of products and services and the latest available statement from Fresenius Medical Care AG & Co. KGaAReasons to Buy- Support sales activities by understanding your customers’ businesses better- Qualify prospective partners and suppliers- Keep fully up to date on your competitors’ business structure, strategy and prospects- Obtain the most up to date company information availableTable of Contents :SWOT COMPANY PROFILE: Fresenius Medical Care AG & Co. KGaAKey Facts: Fresenius Medical Care AG & Co. KGaACompany Overview: Fresenius Medical Care AG & Co. KGaABusiness Description: Fresenius Medical Care AG & Co. KGaACompany History: Fresenius Medical Care AG & Co. KGaAKey Employees: Fresenius Medical Care AG & Co. KGaAKey Employee Biographies: Fresenius Medical Care AG & Co. KGaAProducts & Services Listing: Fresenius Medical Care AG & Co. KGaAProducts & Services Analysis: Fresenius Medical Care AG & Co. KGaASWOT analysis: Fresenius Medical Care AG & Co. KGaA*Strengths: Fresenius Medical Care AG & Co. KGaA*Weaknesses: Fresenius Medical Care AG & Co. KGaA*Opportunities: Fresenius Medical Care AG & Co. KGaA*Threats: Fresenius Medical Care AG & Co. KGaACompany View: Fresenius Medical Care AG & Co. KGaATop Competitors: Fresenius Medical Care AG & Co. KGaALocation and Subsidiary: Fresenius Medical Care AG & Co. KGaA*Head Office: Fresenius Medical Care AG & Co. KGaA*Other Locations and Subsidiaries: Fresenius Medical Care AG & Co. KGaAFor more information please visit :http://www. aarkstore. com/reports/Fresenius-Medical-Care-AG-Co-KGaA-SWOT-Analysis-26000. html

Drug Eluting Stents are used for the treatment of heart patients to prevent the need for more-invasive procedures, such as coronary artery bypass surgery. This reduces the need for repeated hospitalization and angioplasty procedures, thus reducing risks due to complications such as heart attack and stroke. The Global Drug Eluting Stent market has been registering a significant growth in the recent past. This market is witnessing a consolidation of major players through strategic alliances. Moreover, the Drug Eluting Stent providers are looking forward to expand their product portfolio to provide a full range of interventional therapies to the physicians and patients. The growth in the demand for the Drug Eluting Stent is due to its increasing acceptance as a viable treatment. Moreover, the growth is fueled by the robust economic growth and a greater adoption of social security schemes in the Asian regions. There are a large number of patients opting for these treatments so as to enhance their quality of life. Further, developed countries provide simple reimbursement options for higher-priced Drug Eluting Stent, which makes them affordable for patients. Moreover reimbursements by national medical savings schemes play a crucial role in the demand for the Drug Eluting Stents. The report by TechNavio Insights forecasts the drug eluting stents market size of the over the period 2008-2012. Further, it discusses the segmentation of the drug eluting stents market into various geographic regions. It also identifies the key market trends, drivers and challenges and profiles some of the key vendors of this market For more information please contact :http://www. aarkstore. com/reports/Global-Drug-Eluting-Stent-Market-2008-2012-37649. html http://blogs. aarkstore. com/ From:Aarkstore Enterprise Contact: Neel Email: press@aarkstore. com http://www. aarkstore. com

The prevalence of diabetes is on the rise across the globe due to increased life expectancy, changing lifestyles, and the rising incidence of obesity. Brazil’s diabetes drugs market is showing a double digit growth rate; while the Russian insulin market is also expected to witness significant growth with an estimated 20 million patients in the region requiring diabetes treatment by 2025.

India and China have the highest number of diabetics in the world – China alone is expected to have more than 71 million diabetic patients by 2025; and the similarly huge patient-base in India has already attracted a number of pharmaceutical companies such as Eli Lilly and Novo Nordisk. These companies are offering simple-to-use insulin versions to grab the market share in the Indian market for diabetes drugs. Thus, diabetes drugs market in BRIC economies is expected to have significant growth opportunities in the years to come. For more, visit : http://www. visionshopsters. com/product/2641/BRIC-Diabetes-Drugs-Market. html

Market Estimates and Forecasts

The report categorizes the BRIC Diabetes Drugs market as follows :• Injectables Market (Insulin, exenatide)• Oral Drugs Market (Metformin, Sulfonylureas, thaizolidinediones, dipeptidyl inhibitors, meglitinides, alpha glucosidase inhibitors, combination medications)

In addition to market tables for each submarket, each section of the report will provide market trends, drivers, and opportunities. The report also draws a competitive landscape, profiling the key players and the top-selling products in the diabetes drug market in BRIC.

What makes our reports unique?

- We provide the longest market segmentation chain in this industry- not many reports provide market breakdown upto level 5. – We provide 10% customization. Normally it is seen that clients do not find specific market intelligence that they are looking for. Our customization will ensure that you necessarily get the market intelligence you are looking for and we get a loyal customer. – We conduct detailed market positioning, product positioning and competitive positioning. Entry strategies, gaps and opportunities are identified for all the stakeholders. – Comprehensive market analysis for the following sectors:- Pharmaceuticals, Medical Devices, Biotechnology, Semiconductor and Electronics, Energy and Power Supplies, Food and Beverages, Chemicals, Advanced Materials, Industrial Automation, and Telecom and IT.

We also analyze retailers and super-retailers, technology providers, and research and development (R&D) companies.

Key questions answered

- Which are the high-growth segments/cash cows and how is the market segmented in terms of oral drugs, injectables?- What are market estimates and forecasts; which markets are doing well and which are not?- Where are the gaps and opportunities; what is driving the market?- Which are the key playing fields? Which are the winning edge imperatives?- How is the competitive outlook; who are the main players in each of the segments; what are the key selling products; what are their strategic directives, operational strengths and product pipelines? Who is doing what?

Powerful Research and analysis

The analysts come from renowned publishers and market research firms, globally, adding their expertise and domain understanding. We get the facts from over 22,000 news and information sources, a huge database of key industry participants and draw on our relationships with more than 900 market research companies across the world. We, at MarketsandMarkets, are inspired to help our clients grow by providing qualitative business insights with our huge market intelligence repository.

For more information on the report, kindly visit :http://www. visionshopsters. com/product/2641/BRIC-Diabetes-Drugs-Market. htmlor email us your query at : info@visionshopsters. com———————————————-